<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00200200</url>
  </required_header>
  <id_info>
    <org_study_id>04-086</org_study_id>
    <nct_id>NCT00200200</nct_id>
    <nct_alias>NCT00263848</nct_alias>
  </id_info>
  <brief_title>Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combination With Chemotherapy With/Without Bevacizumab for Hepatic Metastases From Colorectal Cancer</brief_title>
  <official_title>Randomized Ph II Study of Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combination With IV Systemic Chemo With/Without Bevacizumab (mAB to Vascular Endothelial Growth Factor-A) in Patients With Resected Hepatic Metastases From Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the addition of bevacizumab, to hepatic&#xD;
      arterial therapy with floxuridine (FUDR) and dexamethasone (Dex) (regional chemotherapy), and&#xD;
      either oxaliplatin or CPT-11, plus 5-fluorouracil and leucovorin (systemic chemotherapy) will&#xD;
      increase disease free survival in patients who have undergone liver resection. The patient&#xD;
      will be randomized (a computer generated decision as in the flip of a coin) to receive, or&#xD;
      not to receive bevacizumab in addition to regional and systemic chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 19, 2004</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine whether the addition of concurrent intravenous bevacizumab to HAI plus systemic chemotherapy increases the time to progression in patients with completely resected hepatic metastases from colorectal cancer</measure>
    <time_frame>7.5 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess toxicity</measure>
    <time_frame>7.5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the expression pattern of VEGFR1, VEGFR2 (angiogenesis), and VEGFR3 (lymphangiogenesis) and their cognate ligands (VEGF-A, VEGF-C, VEGF-D), and correlate with patient progression and survival following</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare plasma levels of VEGF-A, VEGF-C, VEGF-D, and CD133+ VEGFR2+ circulating endothelial progenitors</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">73</enrollment>
  <condition>Hepatic Metastases</condition>
  <condition>Colon Cancer</condition>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bevacizumab in addition to HAI plus systemic chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HAI plus systemic chemotherapy alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab HAI plus systemic chemotherapy</intervention_name>
    <description>Oxaliplatin (mg/m2) IV, over 2 hours, 5 FU (mg/m2) continuous infusion, over two days, leucovorin (mg/m2) IV, over 2 hours</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HAI plus systemic chemotherapy</intervention_name>
    <description>Irinotecan (mg/m2) IV, over 30 minutes, 5 FU (mg/m2) continuous infusion over two days, leucovorin (mg/m2) IV, over 30 minutes</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  History of histologically confirmed colorectal adenocarcinoma metastatic to the liver&#xD;
             with no clinical or radiographic evidence of extrahepatic disease. Confirmation of&#xD;
             diagnosis must be performed at MSKCC.&#xD;
&#xD;
          -  Potentially completely resectable hepatic metastases without current evidence of other&#xD;
             metastatic disease.&#xD;
&#xD;
          -  Abdominal and pelvic CT scans and chest CT or x-ray within 6 weeks prior to&#xD;
             registration. (MRI of abdomen may be substituted for CT of abdomen.)&#xD;
&#xD;
          -  Lab values within 14 days prior to registration:&#xD;
&#xD;
               -  WBC ≥ 3.0 K/uL&#xD;
&#xD;
               -  ANC &gt; 1.5 K/uL&#xD;
&#xD;
               -  Platelets ≥ 75 K/uL&#xD;
&#xD;
               -  Total bilirubin &lt; 1.5 mg/dL&#xD;
&#xD;
               -  INR &lt; 1.5&#xD;
&#xD;
               -  Creatinine &lt; 2.0 mg/dL&#xD;
&#xD;
               -  HGB ≥ 9 gm/dL&#xD;
&#xD;
          -  Prior chemotherapy is acceptable if last dose given ≥ 3 weeks prior to registration to&#xD;
             this study. [Note: no chemotherapy to be given after resection of liver lesions prior&#xD;
             to treatment on this study.]&#xD;
&#xD;
          -  KPS ≥ 70%&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Patient age must be &gt;18&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior radiation to the liver. (Prior radiation therapy to the pelvis is acceptable if&#xD;
             completed at least 4 weeks prior to registration.)&#xD;
&#xD;
          -  Active infection, ascites, hepatic encephalopathy.&#xD;
&#xD;
          -  Prior treatment with HAI FUDR.&#xD;
&#xD;
          -  Female patients who are pregnant or lactating.&#xD;
&#xD;
          -  Subjects discovered to have ≥1+ proteinuria at baseline will undergo a 24-hour urine&#xD;
             collection, which must be an adequate collection and must demonstrate &lt;1 g of&#xD;
             protein/24 hours to allow participation in this study.&#xD;
&#xD;
          -  Patients may not be receiving any other investigational agents&#xD;
&#xD;
          -  Patients with known brain metastases that would confound the evaluation of neurologic&#xD;
             and other adverse events will be excluded. Patients with history of primary CNS&#xD;
             tumors, seizures not well-controlled with standard medical therapy, or history of&#xD;
             stroke will also be excluded.&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to bevacizumab.&#xD;
&#xD;
          -  Serious or non-healing active wound, ulcer, or bone fracture&#xD;
&#xD;
          -  Major surgical procedure, open biopsy or significant traumatic injury within 28 days&#xD;
             prior to Day 1 of protocol treatment. (Surgery performed to resect metastatic lesions&#xD;
             and place pump will not exclude patient from protocol; Day 1 of protocol treatment&#xD;
             will take place no sooner than 28 days after surgery.)&#xD;
&#xD;
          -  Current or recent use of a thrombolytic agent.&#xD;
&#xD;
          -  Chronic daily treatment with aspirin (&gt; 325 mg/d) or nonsteroidal anti-inflammatory&#xD;
             medications known to inhibit the platelet function.&#xD;
&#xD;
          -  Presence of bleeding diathesis or coagulopathy.&#xD;
&#xD;
          -  History of serious systemic disease, including myocardial infarction within the last&#xD;
             12 months, uncontrolled hypertension (blood pressure of &gt; 160/110 mmHg on medication),&#xD;
             unstable angina within the last 12 months, New York Heart Association (NYHA) Grade II&#xD;
             or greater congestive heart failure (see Appendix C), unstable symptomatic arrhythmia&#xD;
             requiring medication (subjects with chronic atrial arrhythmia, i. e. atrial&#xD;
             fibrillation or paroxysmal supraventricular tachycardia are eligible), or peripheral&#xD;
             vascular disease (Grade II or greater).&#xD;
&#xD;
          -  Patients with a history of stroke or transient ischemic attack.&#xD;
&#xD;
          -  Presence of central nervous system or brain metastases.&#xD;
&#xD;
          -  Patients who have a diagnosis of Gilbert's disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nancy Kemeny, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Basking Ridge (Follow Up Only)</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Commack (Follow Up Only)</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Westchester (Follow Up Only)</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau (Follow Up Only)</name>
      <address>
        <city>Uniondale</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org</url>
    <description>Memorial Sloan-Kettering Cancer Center</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BEVACIZUMAB (AVASTIN)</keyword>
  <keyword>DEXAMETHASONE</keyword>
  <keyword>FLOXURIDINE</keyword>
  <keyword>FLUOROURACIL</keyword>
  <keyword>IRINOTECAN (CPT-11) CAMPTOSAR</keyword>
  <keyword>LEUCOVORIN</keyword>
  <keyword>OXALIPLATIN</keyword>
  <keyword>Colon</keyword>
  <keyword>Rectal</keyword>
  <keyword>04-086</keyword>
  <keyword>Adjuvant postoperative chemo for CLM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

